Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
SD-169
As low as
71
CHF
CHF 71.00
In stock
Only %1 left
SYN-1079-M0011 mgCHF 71.00
SYN-1079-M0055 mgCHF 92.00
SYN-1079-M01010 mgCHF 106.00
SYN-1079-M05050 mgCHF 341.00
SYN-1079-M100100 mgCHF 497.00
| Product Details | |
|---|---|
| Synonyms | SD169 |
| Product Type | Chemical |
| Properties | |
| Formula | C9H8N2O |
| MW | 160.2 |
| CAS | 1670-87-7 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO or ethanol. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: MAPK - p38 | Kinase Group: CMGC | Substrate: Serine-Threonine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | GQMYQEAXTITUAE-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
SD169 is an orally available, ATP-competitive, isoenzyme-selective Mitogen-Activated Protein Kinase (MAPK) inhibitor. It is 38 times more potent against p38α MAP kinase (IC(50) of 3.2nM) over p38β MAP kinase (IC(50) of 122nM).
Product References
- Preventive and therapeutic potential of p38 alpha-selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with type 1 diabetes: S. Medicherla, et al.; J. Pharmacol. Exp. Ther. 318, 99 (2006)